Endo- and myocarditis as a severe complication of immune-related adverse event treatment: a case report
The use of ICIs and the subsequent treatment of irAEs with immunosuppressants introduce a new subset of immunocompromised patients at risk for fungal infections. While alternative corticosteroid-sparing immune-modulating agents such as biologicals, intravenous immunoglobulins, and disease-modifying anti-rheumatic drugs have been explored, there is lack of prospective studies evaluating their efficacy and safety in this context.
Authors
- Laure-Anne Teuwen (ORCID: https://orcid.org/0000-0003-1690-8198)
- Pieterjan Vanclooster (ORCID: https://orcid.org/0009-0001-6408-4181)
- Jan Van Offenwert (ORCID: https://orcid.org/0000-0002-2458-742X)
- Laura van den Bosch
- Constantijn Franssen (ORCID: https://orcid.org/0000-0002-7085-5317)
Institutions
- University of Antwerp (BE)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- European Heart Journal - Case Reports
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1093/ehjcr/ytaf058
- Citations
- 1
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Fondation contre le Cancer